for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

IsoRay, Inc.

ISR

Latest Trade

0.37USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.27

 - 

0.61

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
0.37
Open
--
Volume
--
3M AVG Volume
2.74
Today's High
--
Today's Low
--
52 Week High
0.61
52 Week Low
0.27
Shares Out (MIL)
67.34
Market Cap (MIL)
24.96
Forward P/E
-4.36
Dividend (Yield %)
--

Next Event

Q4 2019 IsoRay Inc Earnings Release

Latest Developments

More

IsoRay Files Prospectus Relating To Offering & Resale By Selling Stockholders Of Up To 5.8 Mln Shares

IsoRay Q3 Loss Per Share $0.02

Isoray Announces A New Training Collaboration With Texas Oncology

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About IsoRay, Inc.

IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.

Industry

Medical Equipment & Supplies

Contact Info

350 Hills St Ste 106

+1.509.3751202

https://isoray.com/

Executive Leadership

Michael W. McCormick

Chairman of the Board, Director

Lori A. Woods

Interim Chief Executive Officer, Director

Jennifer Streeter

Interim Chief Operating Officer, Vice President of Human Resources

Mark John Austin

Principal Accounting Officer, Co-Principal Financial Officer, Controller

Michael Krachon

Vice President, Director of Sales and Marketing

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.090

2017

-0.110

2018

-0.120

2019(E)

-0.085
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.57
Price To Book (MRQ)
2.90
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-78.02
Return on Equity (TTM)
-67.80

Latest News

BRIEF-Isoray Announces Disposable Delivery System For Custom Intra-Operative Strands For Prostate Cancer Treatment

* ISORAY ANNOUNCES THE FIRST DISPOSABLE DELIVERY SYSTEM FOR CUSTOM INTRA-OPERATIVE STRANDS FOR PROSTATE CANCER TREATMENT Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-IsoRay Inc Enters A Sales Agreement With H.C. Wainwright & Co

* ISORAY INC - ON MAY 8, 2018, CO ENTERED INTO A SALES AGREEMENT WITH H.C. WAINWRIGHT & CO., LLC - SEC FILING

BRIEF-Isoray Reports Q3 LOSS PER SHARE $0.02

* ISORAY ANNOUNCES THIRD QUARTER FISCAL 2018 REVENUE OF $1.57 MILLION, 23 PCT THIRD QUARTER-OVER-THIRD QUARTER INCREASE

BRIEF-Isoray Reports Q2 Loss Per Share Of $0.03

* ISORAY ANNOUNCES SECOND QUARTER FISCAL 2018 REVENUE OF $1.54 MILLION, 50 PCT SECOND QUARTER-OVER-SECOND QUARTER INCREASE

BRIEF-Isoray Inc Preliminary Q2 Revenue $1.54 Million

* ISORAY ANNOUNCES PRELIMINARY SECOND QUARTER F2018 REVENUE OF $1.54 MILLION, 50% YEAR-OVER-YEAR INCREASE

BRIEF-Isoray Says Notified Al & J Media Of Decision To Terminate Media Advertising Agreement Between Parties

* ISORAY SAYS ON DEC 29, 2017, CO NOTIFIED AL & J MEDIA INC OF ITS DECISION TO TERMINATE MEDIA ADVERTISING AGREEMENT BETWEEN PARTIES - SEC FILING Source text: (http://bit.ly/2CTpIiQ) Further company coverage:

BRIEF-IsoRay Q1 loss per share $0.03

* IsoRay announces first quarter fiscal 2018 financial results

BRIEF-IsoRay Inc announces the launch of a Phase II, multicenter clinical trial

* Announces the launch of a Phase II, multicenter clinical trial with Cesium-131 adjuvant radiation for Retroperitoneal Sarcoma Delivery System (Cards Trial) by University of Louisville, division of surgical oncology Source text for Eikon: Further company coverage:

BRIEF-Isoray Q4 loss per share $0.03

* Isoray announces fourth quarter fiscal 2017 revenue of $1.37 million, 22 pct fourth quarter-over-fourth quarter increase

BRIEF-Isoray Inc's unit enters into consignment agreement

* Isoray says on Aug 25, Isoray Medical, a unit of co, entered into a consignment agreement with Medikorpharma-Ural LLC - SEC filing

BRIEF-Isoray receives FDA response to application for Gammatile

* Isoray receives FDA response to 510(k) application for Gammatile

BRIEF-IsoRay Q3 loss per share $0.02

* Isoray announces third quarter fiscal 2017 financial results

BRIEF-Isoray announces final court approval of class action settlement

* Isoray announces final court approval of class action settlement Source text for Eikon: Further company coverage:

BRIEF-IsoRay Q2 loss per share $0.03

* Says continues to expect stronger second half of fiscal 2017

BRIEF-Isoray Inc's CFO Brien Ragle to resign

* Isoray Inc -on January 16, 2017, Brien Ragle, CFO of co, informed board of his resignation from all positions held with co and its subsidiaries, effective immediately

BRIEF-Isoray Inc. announces launch of newly redesigned corporate website

* Isoray, Inc. announces launch of newly redesigned patient and clinician focused corporate website Source text for Eikon: Further company coverage: ;))

BRIEF-Isoray to pay $3.5 mln to settle shareholder litigation

* Isoray, Inc enters into agreement to settle class action shareholder litigation

BRIEF-IsoRay q4 loss per share $0.02

* Quarterly loss per share $0.02 Source: (http://bit.ly/2cxhHTh) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up